



Panacea Biotec

Innovation in support of life

Press Release:

For Immediate Distribution

Panacea Biotec Gets Pan American Health Organization (PAHO) order for supply of EasyFive-TT Vaccines worth USD 13.49 Million

New Delhi: 4th February 2015: Panacea Biotec, among the largest producer of vaccines and a highly progressive research based pharmaceutical and biotechnology company has been elected for supply of Pentavalent Vaccine DTP-HepB-Hib by Pan American Health Organization (PAHO). The Company has been awarded for supply of 5.99 Million doses of EasyfiveTT (DTP-HepB-Hib) fully liquid pentavalent vaccine for calendar year 2015 & 2016 worth USD 13.49 Million (equivalent to around Rs.83.52 Crores) to meet the requirements of global immunization program.

Commenting on the development Dr. Rajesh Jain, Joint Managing Director, Panacea Biotec Ltd. said "We are pleased with this opportunity of supplying Easyfive-TT vaccines to meet the requirements of PAHO once again after a gap of 3 years. Panacea Biotec has been playing a leadership role in the Vaccines R&D, manufacturing and supply to meet demands of National and International agencies of good quality affordable vaccines for the developing world."

About Panacea Biotec

Panacea Biotec is one of India's leading research-based pharma-biotech companies with established research, manufacturing and marketing capabilities. Panacea Biotec is one of the largest vaccine producers in India and has been amongst the top 40 biotechnology companies (*BioSpectrum – ABLE Survey, July 2014*) and the top 60 pharmaceutical companies (*AIOCD AWACS – MAT May 2014*) in India. The product portfolio of Panacea Biotec includes innovative products in therapeutic areas of oncology, organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular diseases and pediatric immunization vaccines. Panacea Biotec is working on a robust pipeline of high barrier to entry generics and 505(b)(2)s, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like microparticles, liposomes, gastroretentive systems. Panacea Biotec has introduced its products


Panacea Biotec Ltd.

B-1 Extn. / A-27 Mohan Co-operative Industrial Estate, Mathura Road New Delhi -110 044

Ph.: +91-11-41678000/ 9000. Fax: +91-11-26940199

Email: corpcom@panaceabiotec.com

CIN: L33117PB1984PLC022350





Panacea Biotec

Innovation in support of life

in 22 countries across the world including USA and Germany through a combination of strategic collaborations and direct presence in select geographies. The company has research collaborations with leading national and international research organizations and corporations. The company's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. The company has around 2900 employees including around 100 scientists working across 4 R&D centers of the company.

For more information, please contact –

Mr. P. D. Karan

GM - Business Diversification & Corporate Communication

B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate,
Mathura Road, New Delhi – 110044, INDIA


Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)

Fax + 91 11 41578002

Mobile: + 91 9312693040, + 91 9810500539

Email: pdkaran@panaceabiotec.com

Web: www.panaceabiotec.com



Panacea Biotec Ltd.

B-1 Extn. / A-27 Mohan Co-operative Industrial Estate, Mathura Road New Delhi -110 044

Ph.: +91-11-41678000/ 9000, Fax: +91-11-26940199

Email: corpcom@panaceabiotec.com

CIN: L33117PB1984PLC022350